Pharyngitis, also known as sore throat, is an inflammation of the pharynx, which is located behind the throat. Pharyngitis is caused by bacterial or viral infections, and it is most common during the colder months of the year. The most common causes of pharyngitis are measles, adenovirus, chickenpox, croup, whooping cough, and group A streptococcus. Viral infections such as the common cold, influenza, and mononucleosis are also common causes of pharyngitis. According to the Pharyngitis Therapeutics Market, the most commonly prescribed treatments for sore throat are amoxicillin and penicillin.
Pharyngitis Therapeutics Market is a clinical condition characterized by inflammation of the pharynx or back of the throat. Pharyngitis is a painful condition of the throat. Pharyngitis can also cause itching and difficulty swallowing. Pharyngitis is caused by a variety of bacterial and viral agents, the most common of which are measles, adenovirus, high cough, and streptococcus. The most common cause of pharyngitis is a viral infection such as the common cold, influenza, or mononucleosis.
The global Pharyngitis Therapeutics Market is segmented by route of administration into oral, intravenous, and others, with the oral segment expected to hold the largest share in the market during the forecast period due to the ease of availability of oral drugs, as well as ease of drug intake. Because of the effectiveness of over-the-counter drugs and the easy availability of medicines in pharmacies, the pharmacy segment is expected to garner a significant share during the forecast period.
Key Players
Genentech Inc., Adamas
Pharmaceutical Inc., PLIVA HRVATSKA d.o.o., Pfizer Inc., Valeant
Pharmaceuticals International, Inc., Mylan N.V., the GSK group of companies,
Teva Pharmaceutical Industries Ltd., and AbbVie Inc. are among the market's
major players.
Comments
Post a Comment